WVP
TEVA icon

Worth Venture Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Worth Venture Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,020
Closed -$159K – 143
2017
Q3 		$159K Buy
+9,020
New +$203K 0.14% 97

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Worth Venture Partners's TEVA Position: Q4 2017 in Review

Worth Venture Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 9,020 shares — an estimated $159K sold.

Worth Venture Partners first reported a position in TEVA in Q3 2017 and held it in 1 quarter. The position peaked at $159K in Q3 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Worth Venture Partners reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Worth Venture Partners sold 9,020 Teva Pharmaceuticals shares in Q4 2017, an estimated $159K.
  • Worth Venture Partners first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Worth Venture Partners's Teva Pharmaceuticals position peaked at $159K in Q3 2017.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Worth Venture Partners's 13F filing for Q4 2017, filed 1 Feb 2018.